| Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012 | 2665 | 2012 |
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, ... Journal of Biological Chemistry 284 (12), 8023-8032, 2009 | 2104 | 2009 |
| A landscape of pharmacogenomic interactions in cancer F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ... Cell 166 (3), 740-754, 2016 | 1935 | 2016 |
| Developing irreversible inhibitors of the protein kinase cysteinome Q Liu, Y Sabnis, Z Zhao, T Zhang, SJ Buhrlage, LH Jones, NS Gray Chemistry & biology 20 (2), 146-159, 2013 | 756 | 2013 |
| Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders H Jiang, H He, Y Chen, W Huang, J Cheng, J Ye, A Wang, J Tao, C Wang, ... Journal of Experimental Medicine 214 (11), 3219-3238, 2017 | 655 | 2017 |
| Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity H He, H Jiang, Y Chen, J Ye, A Wang, C Wang, Q Liu, G Liang, X Deng, ... Nature communications 9 (1), 2550, 2018 | 617 | 2018 |
| Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 X Deng, N Dzamko, A Prescott, P Davies, Q Liu, Q Yang, JD Lee, ... Nature chemical biology 7 (4), 203-205, 2011 | 487 | 2011 |
| Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu, NS Gray ACS chemical biology 9 (6), 1230-1241, 2014 | 441 | 2014 |
| The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma T Berry, W Luther, N Bhatnagar, Y Jamin, E Poon, T Sanda, D Pei, ... Cancer cell 22 (1), 117-130, 2012 | 393 | 2012 |
| Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities C Hu, J Yang, Z Qi, H Wu, B Wang, F Zou, H Mei, J Liu, W Wang, Q Liu MedComm 3 (3), e161, 2022 | 375 | 2022 |
| Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective … Q Liu, JW Chang, J Wang, SA Kang, CC Thoreen, A Markhard, W Hur, ... Journal of medicinal chemistry 53 (19), 7146-7155, 2010 | 295 | 2010 |
| Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available … Q Liu, J Wang, SA Kang, CC Thoreen, W Hur, T Ahmed, DM Sabatini, ... Journal of medicinal chemistry 54 (5), 1473-1480, 2011 | 258 | 2011 |
| mTOR mediated anti-cancer drug discovery Q Liu, C Thoreen, J Wang, D Sabatini, NS Gray Drug Discovery Today: Therapeutic Strategies 6 (2), 47-55, 2009 | 244 | 2009 |
| Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR Q Liu, C Xu, S Kirubakaran, X Zhang, W Hur, Y Liu, NP Kwiatkowski, ... Cancer research 73 (8), 2574-2586, 2013 | 243 | 2013 |
| Sodium rutin ameliorates Alzheimer’s disease–like pathology by enhancing microglial amyloid-β clearance RY Pan, J Ma, XX Kong, XF Wang, SS Li, XL Qi, YH Yan, J Cheng, Q Liu, ... Science advances 5 (2), eaau6328, 2019 | 226 | 2019 |
| Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma RG Liao, J Jung, J Tchaicha, MD Wilkerson, A Sivachenko, ... Cancer research 73 (16), 5195-5205, 2013 | 208 | 2013 |
| Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent J Ni, Q Liu, S Xie, C Carlson, T Von, K Vogel, S Riddle, C Benes, M Eck, ... Cancer discovery 2 (5), 425-433, 2012 | 197 | 2012 |
| Brown adipose tissue transplantation ameliorates polycystic ovary syndrome X Yuan, T Hu, H Zhao, Y Huang, R Ye, J Lin, C Zhang, H Zhang, G Wei, ... Proceedings of the national academy of sciences 113 (10), 2708-2713, 2016 | 190 | 2016 |
| Rutin ameliorates obesity through brown fat activation X Yuan, G Wei, Y You, Y Huang, HJ Lee, M Dong, J Lin, T Hu, H Zhang, ... The FASEB Journal 31 (1), 333-345, 2017 | 175 | 2017 |
| Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor HG Kim, L Tan, EL Weisberg, F Liu, P Canning, HG Choi, SA Ezell, H Wu, ... ACS chemical biology 8 (10), 2145-2150, 2013 | 161 | 2013 |
Mario NiepelRibon TherapeuticsCorreu electrònic verificat a ribontx.com